CA2931322A1 - Adenovirus expressing immune cell stimulatory receptor agonist(s) - Google Patents

Adenovirus expressing immune cell stimulatory receptor agonist(s) Download PDF

Info

Publication number
CA2931322A1
CA2931322A1 CA2931322A CA2931322A CA2931322A1 CA 2931322 A1 CA2931322 A1 CA 2931322A1 CA 2931322 A CA2931322 A CA 2931322A CA 2931322 A CA2931322 A CA 2931322A CA 2931322 A1 CA2931322 A1 CA 2931322A1
Authority
CA
Canada
Prior art keywords
adenovirus
cells
cancer
competent oncolytic
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2931322A
Other languages
English (en)
French (fr)
Inventor
Frank TUFARO
Juan FUEYO-MARGARETO
Candelaria Gomez-Manzano
Charles Conrad
W.K. Alfred Yung
Hong Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
DNAtrix Inc
Original Assignee
University of Texas System
DNAtrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, DNAtrix Inc filed Critical University of Texas System
Publication of CA2931322A1 publication Critical patent/CA2931322A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2931322A 2013-11-22 2014-11-21 Adenovirus expressing immune cell stimulatory receptor agonist(s) Abandoned CA2931322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907860P 2013-11-22 2013-11-22
US61/907,860 2013-11-22
PCT/US2014/066920 WO2015077624A1 (en) 2013-11-22 2014-11-21 Adenovirus expressing immune cell stimulatory receptor agonist(s)

Publications (1)

Publication Number Publication Date
CA2931322A1 true CA2931322A1 (en) 2015-05-28

Family

ID=53180213

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2931322A Abandoned CA2931322A1 (en) 2013-11-22 2014-11-21 Adenovirus expressing immune cell stimulatory receptor agonist(s)

Country Status (11)

Country Link
US (4) US20160289645A1 (cg-RX-API-DMAC7.html)
EP (2) EP3653714A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016540505A (cg-RX-API-DMAC7.html)
KR (1) KR20160137946A (cg-RX-API-DMAC7.html)
CN (2) CN114317461A (cg-RX-API-DMAC7.html)
AU (1) AU2014352749A1 (cg-RX-API-DMAC7.html)
CA (1) CA2931322A1 (cg-RX-API-DMAC7.html)
DK (1) DK3071697T3 (cg-RX-API-DMAC7.html)
ES (1) ES2765489T3 (cg-RX-API-DMAC7.html)
SG (1) SG10201907841UA (cg-RX-API-DMAC7.html)
WO (1) WO2015077624A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4663241A2 (en) 2010-10-08 2025-12-17 Mesoblast International Sàrl Enhanced msc preparations
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
NO3021859T3 (cg-RX-API-DMAC7.html) 2013-10-25 2018-04-28
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
KR20170109582A (ko) * 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
ES2994611T3 (en) * 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
WO2017103291A1 (en) 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
CN109415703B (zh) 2016-01-08 2024-08-30 雷普利穆内有限公司 经修饰的溶瘤病毒
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
EP3463405A4 (en) * 2016-05-27 2020-02-26 DNAtrix, Inc. Adenovirus and immunomodulator combination therapy
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)
HUE053236T2 (hu) 2016-09-12 2021-06-28 Targovax Oy Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018111902A1 (en) * 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
AU2017379835A1 (en) 2016-12-21 2019-07-11 Dnatrix Armed replication-competent oncolytic adenoviruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN108338994A (zh) 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
CN109276580B (zh) 2017-07-21 2021-08-24 厦门大学 一种用于治疗肿瘤的病毒
KR102776166B1 (ko) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
CN112020510B (zh) 2018-03-19 2024-10-11 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
WO2019191494A1 (en) * 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
EP3775175A4 (en) 2018-04-09 2022-02-09 Salk Institute for Biological Studies ONCOLYTIC ADENOVIRUS COMPOSITIONS WITH IMPROVED REPLICATION PROPERTIES
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
JP7480126B2 (ja) * 2018-09-15 2024-05-09 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020172509A1 (en) * 2019-02-21 2020-08-27 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
KR20220152250A (ko) * 2020-03-06 2022-11-15 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스
WO2021252496A1 (en) * 2020-06-10 2021-12-16 Richard Lowenthal Engineered adenovirus vectors and uses thereof
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
KR20230046298A (ko) 2020-08-10 2023-04-05 메조블라스트 인터내셔널 에스에이알엘 세포 조성물 및 치료 방법
JP7614980B2 (ja) 2021-08-25 2025-01-16 三菱重工航空エンジン株式会社 燃焼器パネル、及びガスタービン用燃焼器
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
JPH11503910A (ja) 1995-04-17 1999-04-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム アデノウイルスヘルパーウイルスシステム
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
EP1044263A2 (en) * 1997-12-02 2000-10-18 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7368527B2 (en) * 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
EP1470233A1 (en) * 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
JP2008531481A (ja) * 2005-02-08 2008-08-14 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 癌の治療のための、ｍｄａ−７を含む組成物および方法
PT1877090E (pt) 2005-05-06 2014-04-15 Providence Health System Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
BRPI0920679A2 (pt) * 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
ES2630328T3 (es) * 2010-08-23 2017-08-21 Board Of Regents, The University Of Texas System Anticuerpos anti-OX40 y procedimientos de uso de los mismos
CA2812096A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Adenoviral vectors and methods and uses related thereto
EP2675933B1 (en) * 2011-02-17 2017-02-08 Alcoa Inc. 2xxx series aluminum lithium alloys
CN104093830A (zh) * 2011-04-15 2014-10-08 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
WO2013112942A1 (en) * 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
SG10201606356YA (en) * 2012-02-02 2016-09-29 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens

Also Published As

Publication number Publication date
JP2016540505A (ja) 2016-12-28
ES2765489T3 (es) 2020-06-09
EP3071697A1 (en) 2016-09-28
CN106029889A (zh) 2016-10-12
CN114317461A (zh) 2022-04-12
AU2014352749A1 (en) 2016-06-09
EP3071697A4 (en) 2017-05-17
EP3653714A1 (en) 2020-05-20
US20160289645A1 (en) 2016-10-06
JP2021137029A (ja) 2021-09-16
US20190093085A1 (en) 2019-03-28
US20250171745A1 (en) 2025-05-29
EP3071697B1 (en) 2019-10-16
US20210301264A1 (en) 2021-09-30
DK3071697T3 (da) 2020-01-27
KR20160137946A (ko) 2016-12-02
SG10201907841UA (en) 2019-10-30
JP2020048582A (ja) 2020-04-02
WO2015077624A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
US20250171745A1 (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
US11090344B2 (en) Adenovirus and immunomodulator combination therapy
JP6325459B2 (ja) 腫瘍関連異種抗原を発現するアデノウイルス
WO2010030002A1 (ja) 外来性ｇｉｔｒリガンド発現細胞
WO2015106697A1 (zh) 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
KR20220116191A (ko) 4-1bbl 아쥬반트화 재조합 변형 백시니아 바이러스 앙카라 (mva)의 의약적 용도
WO2022262764A1 (zh) 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用
US20250064873A1 (en) TNFSF-L Fusion Proteins and Uses Thereof
HK40030022A (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
US20250009797A1 (en) Methods and materials for treating cancer
HK1230236A1 (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
HK40007925A (en) Adenovirus and immunomodulator combination therapy
WO2022262765A1 (zh) 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
Guinn et al. International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China
WO2025006797A1 (en) Il-12 stability variants
CA2937023C (en) Immunity enhancing therapeutic vaccine for hpv and related diseases
WO2022011651A1 (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
Springer et al. 707. Characterization of the Complex Physiological Response to Constitutive VEGF Gene Expression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191112

EEER Examination request

Effective date: 20191112

FZDE Discontinued

Effective date: 20230519